These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 16211050)

  • 1. BIRB-796 is not an effective ABL(T315I) inhibitor.
    O'Hare T; Druker BJ
    Nat Biotechnol; 2005 Oct; 23(10):1209-10; author reply 1210-1. PubMed ID: 16211050
    [No Abstract]   [Full Text] [Related]  

  • 2. A small molecule-kinase interaction map for clinical kinase inhibitors.
    Fabian MA; Biggs WH; Treiber DK; Atteridge CE; Azimioara MD; Benedetti MG; Carter TA; Ciceri P; Edeen PT; Floyd M; Ford JM; Galvin M; Gerlach JL; Grotzfeld RM; Herrgard S; Insko DE; Insko MA; Lai AG; Lélias JM; Mehta SA; Milanov ZV; Velasco AM; Wodicka LM; Patel HK; Zarrinkar PP; Lockhart DJ
    Nat Biotechnol; 2005 Mar; 23(3):329-36. PubMed ID: 15711537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction maps for kinase inhibitors.
    Griffin JD
    Nat Biotechnol; 2005 Mar; 23(3):308-9. PubMed ID: 15765084
    [No Abstract]   [Full Text] [Related]  

  • 4. Analysis of imatinib and sorafenib binding to p38alpha compared with c-Abl and b-Raf provides structural insights for understanding the selectivity of inhibitors targeting the DFG-out form of protein kinases.
    Namboodiri HV; Bukhtiyarova M; Ramcharan J; Karpusas M; Lee Y; Springman EB
    Biochemistry; 2010 May; 49(17):3611-8. PubMed ID: 20337484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358.
    Modugno M; Casale E; Soncini C; Rosettani P; Colombo R; Lupi R; Rusconi L; Fancelli D; Carpinelli P; Cameron AD; Isacchi A; Moll J
    Cancer Res; 2007 Sep; 67(17):7987-90. PubMed ID: 17804707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796.
    Dietrich J; Hulme C; Hurley LH
    Bioorg Med Chem; 2010 Aug; 18(15):5738-48. PubMed ID: 20621496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance.
    Azam M; Nardi V; Shakespeare WC; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Sliz P; Veach DR; Bornmann WG; Clarkson B; Dalgarno DC; Sawyer TK; Daley GQ
    Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9244-9. PubMed ID: 16754879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steered molecular dynamics simulations reveal the likelier dissociation pathway of imatinib from its targeting kinases c-Kit and Abl.
    Yang LJ; Zou J; Xie HZ; Li LL; Wei YQ; Yang SY
    PLoS One; 2009 Dec; 4(12):e8470. PubMed ID: 20041122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorescence lifetime imaging of biosensor peptide phosphorylation in single live cells.
    Damayanti NP; Parker LL; Irudayaraj JM
    Angew Chem Int Ed Engl; 2013 Apr; 52(14):3931-4. PubMed ID: 23450802
    [No Abstract]   [Full Text] [Related]  

  • 10. ONIOM DFT/PM3 calculation on the interaction between STI-571 and abelson tyrosine kinase.
    Xiong YZ; Chen PY
    J Mol Model; 2008 Nov; 14(11):1083-6. PubMed ID: 18663490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Explaining why Gleevec is a specific and potent inhibitor of Abl kinase.
    Lin YL; Meng Y; Jiang W; Roux B
    Proc Natl Acad Sci U S A; 2013 Jan; 110(5):1664-9. PubMed ID: 23319661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors.
    Skora L; Mestan J; Fabbro D; Jahnke W; Grzesiek S
    Proc Natl Acad Sci U S A; 2013 Nov; 110(47):E4437-45. PubMed ID: 24191057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance.
    Tseng PH; Lin HP; Zhu J; Chen KF; Hade EM; Young DC; Byrd JC; Grever M; Johnson K; Druker BJ; Chen CS
    Blood; 2005 May; 105(10):4021-7. PubMed ID: 15665113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conformation-selective inhibitors reveal differences in the activation and phosphate-binding loops of the tyrosine kinases Abl and Src.
    Hari SB; Perera BG; Ranjitkar P; Seeliger MA; Maly DJ
    ACS Chem Biol; 2013 Dec; 8(12):2734-43. PubMed ID: 24106839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site.
    Fabbro D; Manley PW; Jahnke W; Liebetanz J; Szyttenholm A; Fendrich G; Strauss A; Zhang J; Gray NS; Adrian F; Warmuth M; Pelle X; Grotzfeld R; Berst F; Marzinzik A; Cowan-Jacob SW; Furet P; Mestan J
    Biochim Biophys Acta; 2010 Mar; 1804(3):454-62. PubMed ID: 20152788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A molecular mechanics model for imatinib and imatinib:kinase binding.
    Aleksandrov A; Simonson T
    J Comput Chem; 2010 May; 31(7):1550-60. PubMed ID: 20020482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gleevec target Abl important for normal immune activation of T cells.
    Cancer Biol Ther; 2004 Aug; 3(8):704. PubMed ID: 15751157
    [No Abstract]   [Full Text] [Related]  

  • 18. New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.
    O'Hare T; Eide CA; Deininger MW
    Expert Opin Investig Drugs; 2008 Jun; 17(6):865-78. PubMed ID: 18491988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming kinase resistance in chronic myeloid leukemia.
    Lee F; Fandi A; Voi M
    Int J Biochem Cell Biol; 2008; 40(3):334-43. PubMed ID: 18401881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imatinib mesilate-induced phosphatidylinositol 3-kinase signalling and improved survival in insulin-producing cells: role of Src homology 2-containing inositol 5'-phosphatase interaction with c-Abl.
    Mokhtari D; Al-Amin A; Turpaev K; Li T; Idevall-Hagren O; Li J; Wuttke A; Fred RG; Ravassard P; Scharfmann R; Tengholm A; Welsh N
    Diabetologia; 2013 Jun; 56(6):1327-38. PubMed ID: 23462796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.